Related Experiment Video
Updated: Jun 24, 2025
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer
Antoine Mouawad1, Sofia Habib1, Marc Boutros1
1Université Saint-Joseph de Beyrouth, Beyrouth, 11-5076, Lebanon.
Abstract:
Aim: Pancreatic adenocarcinoma is a very aggressive type of cancer, in which targeted therapies have not yet been fully utilized. KRAS wild-type pancreatic adenocarcinoma tumors are associated with different genomic alterations in comparison to KRAS mutated pancreatic adenocarcinoma. Objective: This systematic review aims to provide a one-stop summary of all these alterations, their proposed targeted treatment and their effect on disease progression. Methods: An electronic search strategy was elaborated in the PubMed database between 2020 and January 2024. Results: 21 studies were included, and we found that the most frequent targetable genomic alterations in KRAS wild-type pancreatic adenocarcinoma were BRAF, EGFR, FGFR, MSI-H/dMMR, Her2/ERBB2 amplification, BRCA1/2 and other HRDs, and gene fusions like ALK, NTRK and NRG1.
Insights
Targetable genomic alterations in KRAS wild-type pancreatic adenocarcinoma, such as BRAF and EGFR, offer new treatment avenues. This review summarizes these alterations and their impact on cancer progression.
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Pancreatic adenocarcinoma is an aggressive cancer with limited targeted therapy options.
- KRAS wild-type tumors exhibit distinct genomic alterations compared to KRAS-mutated ones.
Conclusions:
- Identification of specific targetable genomic alterations in KRAS wild-type pancreatic cancer.
- Provides a foundation for developing targeted therapies for this patient subgroup.
